Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors

Diabetes mellitus (DM) is believed to be the third most frequent direct cause of death after cardiovascular and oncological diseases. Therefore, solutionof DM-related problems is a major challenge facing health authorities in many countries. No doubt, strict control of glycemia is an indispensableco...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander Sergeevich Ametov, Ekaterina Vladimirovna Karpova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	diabetes mellitus dpp-4 inhibitors galvus-met Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/79d30283e9ec4221af5b1c7afe77a1d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:79d30283e9ec4221af5b1c7afe77a1d9
record_format	dspace
spelling	oai:doaj.org-article:79d30283e9ec4221af5b1c7afe77a1d92021-11-14T09:00:15ZEfficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors2072-03512072-037810.14341/2072-0351-5677https://doaj.org/article/79d30283e9ec4221af5b1c7afe77a1d92010-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5677https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Diabetes mellitus (DM) is believed to be the third most frequent direct cause of death after cardiovascular and oncological diseases. Therefore, solutionof DM-related problems is a major challenge facing health authorities in many countries. No doubt, strict control of glycemia is an indispensablecondition for the reduction of the frequency of diabetic complications. Indeed, many strategies developed in the recent years allowed metabolic controlin DM patients to be significantly improved. Basic and clinical research of the last decade provided a basis for the development of highly promisingtrends in the treatment of CD2, such as the use of incretins. Inhibitors of dipeptylpeptidase-4 (DPP-4) including Galvus (vildagliptin) and GalvusMet (vildagliptin + metformin) have been available in this country for the last 2 years. International studies showed high efficiency and safety of bothagents. They help to achieve adequate glycemic control in the absence of side effects and complications. Galvus significantly reduces daily variabilityof glycemia that is known to be a risk factor of severe vascular complications of DM. Another advantage of these drugs is they can be used by agedpatients at risk of cardiovascular disorders suffering hypertension. An example of combined therapy using Galvus Met in a DM2 patient is presenteddemonstrating markedly improved glycemic control, blood glucose dynamics, and quality of life. Galvus and Galvus Met can be prescribed as aninitial treatment in combination with all traditional oral hypoglycemic agents and insulin.Alexander Sergeevich AmetovEkaterina Vladimirovna KarpovaEndocrinology Research Centrearticlediabetes mellitusdpp-4 inhibitorsgalvus-metNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 2, Pp 69-75 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus dpp-4 inhibitors galvus-met Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus dpp-4 inhibitors galvus-met Nutritional diseases. Deficiency diseases RC620-627 Alexander Sergeevich Ametov Ekaterina Vladimirovna Karpova Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
description	Diabetes mellitus (DM) is believed to be the third most frequent direct cause of death after cardiovascular and oncological diseases. Therefore, solutionof DM-related problems is a major challenge facing health authorities in many countries. No doubt, strict control of glycemia is an indispensablecondition for the reduction of the frequency of diabetic complications. Indeed, many strategies developed in the recent years allowed metabolic controlin DM patients to be significantly improved. Basic and clinical research of the last decade provided a basis for the development of highly promisingtrends in the treatment of CD2, such as the use of incretins. Inhibitors of dipeptylpeptidase-4 (DPP-4) including Galvus (vildagliptin) and GalvusMet (vildagliptin + metformin) have been available in this country for the last 2 years. International studies showed high efficiency and safety of bothagents. They help to achieve adequate glycemic control in the absence of side effects and complications. Galvus significantly reduces daily variabilityof glycemia that is known to be a risk factor of severe vascular complications of DM. Another advantage of these drugs is they can be used by agedpatients at risk of cardiovascular disorders suffering hypertension. An example of combined therapy using Galvus Met in a DM2 patient is presenteddemonstrating markedly improved glycemic control, blood glucose dynamics, and quality of life. Galvus and Galvus Met can be prescribed as aninitial treatment in combination with all traditional oral hypoglycemic agents and insulin.
format	article
author	Alexander Sergeevich Ametov Ekaterina Vladimirovna Karpova
author_facet	Alexander Sergeevich Ametov Ekaterina Vladimirovna Karpova
author_sort	Alexander Sergeevich Ametov
title	Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
title_short	Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
title_full	Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
title_fullStr	Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
title_full_unstemmed	Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
title_sort	efficacious and safe management of type 2 diabetes mellitus using dpp-4 inhibitors
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/79d30283e9ec4221af5b1c7afe77a1d9
work_keys_str_mv	AT alexandersergeevichametov efficaciousandsafemanagementoftype2diabetesmellitususingdpp4inhibitors AT ekaterinavladimirovnakarpova efficaciousandsafemanagementoftype2diabetesmellitususingdpp4inhibitors
_version_	1718429662535745536

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors

Ejemplares similares